Jinfiniti Biotech is a biomedical research and service firm for biomarkers and novel therapeutics using high throughput and high content technologies. Jinfiniti is currently providing research services to both biomedical research institutions and pharmaceutical companies with unique research reagents and platforms including nucleic acid isolation, molecular biology, fully human monoclonal antibodies, Luminex and ELISA assays, proteomics, in vitro and invivo screening for multi-drug resistance and evaluation of synergistic effects of drug combinations. Its long term goal is to develop novel clinical assays for risk assessment, early diagnosis and therapeutic monitoring of human diseases, especially for diabetic complications and cancer. Its unique platform capable of rapidly producing large numbers of fully human monoclonal antibodies will lead to the development of novel therapeutics for cancer and immunological diseases.
||Isolations Done to Date!